FOLH1 and posterior cortical atrophy: Gallium-68 prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is currently revolutionizing the PCa diagnostic pathway and has shown value as a means of detecting biochemical recurrence and staging of high-risk PCa [14, 15], and it is the most promising method for identifying patients with CSPCa among suspected PCa patients with a negative mpMRI [16].